Ginkgo, Agenus win $31M contract to research adjuvants [Seeking Alpha]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Seeking Alpha
U.S. government to develop next-generation vaccine adjuvants, the companies announced Thursday. While Ginkgo ( DNA ) shares gained after the announcement, Agenus ( AGEN lost ~34% during regular trading after the immuno-oncology company announced a 1-for-20 reverse stock split to remain compliant with Nasdaq listing requirements. The Defense Threat Reduction Agency (DTRA), a division under the U.S. Department of Defense, has awarded the five-year contract. Per the terms, Ginkgo ( DNA ) and SaponiQx will design adjuvants using the latter's adjuvant-generating platform. Adjuvants are designed to improve vaccine efficacy. SaponiQx's saponin-based adjuvant, Stimulon QS-21, is a key component in shingles, malaria, and respiratory syncytial virus (RSV) vaccines. Cell platform company Ginkgo ( DNA ) first partnered with SaponiQx for adjuvant-related studies in 2021. "We're very excited by this opportunity to strengthen and expand the SaponiQx-Ginkgo partnership and to work with DTRA
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingBusiness Wire
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Agenus to Provide First Quarter 2024 Financial Report and Corporate UpdateBusiness Wire
- Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
AGEN
Earnings
- 3/14/24 - Miss
AGEN
Analyst Actions
- 3/18/24 - HC Wainwright
AGEN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/22/24 - Form 4
- AGEN's page on the SEC website